Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms
US11123310B2 · kind B2 · utility
3Cited by
5References
43Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 24, 2017 |
| Grant date | Sep 21, 2021 |
| Priority date | — |
| Expiry date | Oct 6, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/64
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.